drugset / Trial / NCT00633685

Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure

NCT00633685

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Three hundred (300) male or female outpatients, over 18 years of age, will be enrolled in this study to determine whether fluoxetine can be used as a treatment for Posttraumatic Stress Disorder in soldiers recently returning from combat exposure. There will be two phases to the study. In Phase I Fluoxetine + usual psychological care will be compared with Placebo + usual psychological care over a 12-week period. Subsequently, in Phase II all subjects will be offered the opportunity to enroll in a 20-week open-label trial on Fluoxetine. If response is inadequate, adjunctive treatment with either buspirone or bupropion will be offered. The investigational drugs are Fluoxetine, Buspirone and Bupropion. All are commercially available.

Timeline

Start
2010-03
Primary completion
2012-06
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 20 mg
Subject Fluoxetine Small molecule 60 mg
Subject Fluoxetine Small molecule 80 mg